VISN 5 MIRECC General Publications 2003-2004 - MIRECC / CoE
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

MIRECC / CoE

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
 

VISN 5 MIRECC General Publications 2003-2004

 

About Us • Clinical • Education • Research
VISN 5 MIRECC home

 

Arango C, Breier A, McMahon R, Carpenter Jr., WT, Buchanan RW. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. American Journal of Psychiatry, 160:1421-1427, 2003.

Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT Jr. The deficit syndrome in schizophrenia: Implications for the treatment of negative symptoms. European Psychiatry 19:21-26, 2004.

Arango C, Summerfelt A, Buchanan RW. Olanzapine effects on auditory sensory gating in schizophrenia. American Journal of Psychiatry 160:2066-2068, 2003.

Avila MT, Adami HM, McMahon RP, Thaker GK. Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype Schizophr Bull. 2003;29(2):299-309.

Avila MT, Sherr JD, Hong E, Meyers C, Thaker GK: Effects of Nicotine on leading saccades during smooth pursuit eye movements in smoking and non-smoking schizophrenia patients. Neuropsychopharmacology, 28:2184-2192, 2003.

Bellack, A.S. (2003). Psychosocial Rehabilitation. In A. Tasman, J. Lieberman, & J. Kay (Eds.), Psychiatry: (second edition). London: Wiley.

Bellack, A.S. Skills training for people with severe mental illness. Psychiatric Rehabilitation Journal, 27:375-391, 2004.

Bellack, A.S., Mueser, K.T., Gingerich, S., & Agresta, J. Social skills training for schizophrenia: A step-by-step guide (second edition). New York: Guilford, 2004.

Bellack, A.S., Schooler, N.R., Marder, S.R., Kane, J.M., Brown, C.H., & Yang, Y. Do clozapine and risperidone affect social competence and problem solving? American Journal of Psychiatry, 161, 364-367, 2004.

Buchanan RW, Francis A, Arango C, Miller K, Lefkowitz DM, McMahon RP, Barta PE, Pearlson GD. Morphometric assessment of the heteromodal association cortex in schizophrenia. American Journal of Psychiatry 161(2):322-331, 2004.

Busch A, Frank RG, Lehman AF: The effect of a managed behavioral health care carve-out on quality of care for medicaid patients diagnosed with schizophrenia. Archives of General Psychiatry, 61:442-448, 2004.

Carpenter WT and Koenig JI. Molecular Medicine and the Prospects for Prevention and Early Intervention in Schizophrenia. In: Early Clinical Intervention and Prevention in Schizophrenia. Stone WS, Faraone SV and Tsuang MT (eds). Humana Press, Inc., Totowa, NJ, pp. 355-366, 2004.

Conley RR, Kelly DL, Richardson C, Tamminga CA, Carpenter WT. The efficacy of high-dose Olanzapine versus Clozapine in treatment-resistant schizophrenia: A double-blind crossover study. [Letter to the Editor]. Journal of Clinical Psychopharmacology, 23(6):1-3, 2003.

Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE: Prevalence and Correlates of Obesity in a Community Sample of Individuals with Severe and Persistent Mental Illness. Journal of Nervous and Mental Disease, 191(12):799-805, 2003.

Dickerson FB, McNary SW, Brown CH, Kreyenbuhl J, Goldberg RW, Dixon L Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. Medical Care, 4:560-570, 2003.

Dickinson D, Iannone VN, Wilk CM, Gold JM. General and specific cognitive deficits in schizophrenia. Biological Psychiatry; 55(8):826-833, 2004.

Dickinson, D., Iannone, V.N., Wilk, C., & Gold, J.M. General and Specific Cognitive Deficits in Schizophrenia. Biological Psychiatry, April, 55, 826-833, 2004.

Dixon L, Goldman HH: Forty Years of Progress in Community Mental Health: The Role of Evidence-based Practices, The Australian and New Zealand Journal of Psychiatry, 37(6): 668-673, 2003.

Dixon L, Kreyenbuhl J, Dickerson F, Donner T, Brown C, Wohlheiter K, Postrado L, Goldberg R, Messias E, Fang LJ: A Comparison of Type 2 Diabetes Outcomes Among Individuals With and Without Severe Mental Illnesses, Psychiatric Services, 55:892-900, 2004.

Dixon L, Lucksted A, Stewart B, Burland J, Brown C, Postrado L, McGuire C, Hoffman M.: Outcomes of the Peer-Taught 12-Week Family-to-Family Education Program for Severe Mental Illness, Acta Psychiatrica Scandinavica, 109:207-215, 2004.

Dwivedi, Y., H.S. Rizavi, RR Conley, R.C. Roberts, C.A. Tamminga, and G.N. Pandey Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine receptor kinase B in postmortem brain of suicide subjects. Archives of General Psychiatry., 60:804-815, 2003.

Frank RG, Berndt ER, Busch AB, Lehman AF: Quality-constant price indexes for the ongoing treatment of schizophrenia: An exploratory study. Special Issue of the Quarterly Review of Economics and Finance, National Bureau of Economic Research, Inc., 22:390-409, 2004.

Gearon, J.S., Bellack, A.S., & Tenhula, W.N. (2004). Preliminary reliability and validity of the clinician-administered PTSD scale for schizophrenia. Journal of Consulting and Clinical Psychology, 72(1), 121-125.

Hong LE, Summerfelt A, McMahon RP, Thaker GK, Buchanan RW: Gamma/Beta Oscillation and Sensory Gating Deficity in Schizophrenia. Neuro Report, 15:155-159, 2004.

Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research; 68(2-3):283-297, 2004.

Keefe RSE, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M. Neurocognitive assessments in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin; 29(1):45-55, 2003.

Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Annuals of Clinical Psychiatry, 15(3-4):181-186, 2003.

Kirkpatrick B, Kakoyannis A. Sexual dimorphism and the NMDA receptor in alloparental behavior in juvenile prairie voles. Behavioral Neuroscience 118:584-589, 2004.

Kirkpatrick B, Messias NC, Conley RR, Roberts RC. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia. Journal of Nervous and Mental Disease 191:563-567, 2003.

Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF: Racial disparity in the pharmacological management of schizophrenia. Schizophrenia Bulletin, 29(2):183-193, 2003.

Lehman AF, Buchanan RW, Dickerson FB, Dixon L, Goldberg R, Green-Paden L, Kreyenbuhl J. Evidence-based treatment for Schizophrenia. Psychiatric Clinics of North America, 26:939-954, 2003.

Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH: The schizophrenia care and assessment project health questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care. Schizophrenia Bulletin, 29(2):247-256, 2003.

Lehman AF, Goldman HH, Dixon LB, Churchill R: Evidence-based mental health treatments and services: Examples to inform public policy. Milbank Memorial Fund, 1-32, 2004.

Lehman AF, Kreyenbuhl J, Buchanan R, Dickerson F, Dixon L, Goldberg R, Green-Paden L, Tenhula W, Boerescu D, Tek C, Sandson N, Steinwachs D: The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003, Schizophrenia Bulletin, 30 (2):193-217, 2004.

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd Edition. American Journal of Psychiatry, Supplement, 161(2):1-56, 2004.

Levine RJ, Carpenter WT, Appelbaum PS. Clarifying standards for using placebos [Letter to the Editor]. Science, Vol. 300, pp. 1659-1661, 13 June 2003.

Lindsey R, Weist M, LeBeau LS, Rosner L, Dixon L, Pruitt D: The Significance of Self-Reported Drug or Alcohol Use for Inner-City Teenagers, Psychiatric Services, 2004, 55: 824-6.

Lucksted A, McGuire C, Postrado L, Kreyenbuhl J, Dixon L: Specifying Cigarette Smoking & Quitting among People with Serious Mental Illness, American Journal of Addictions, 2004: 13, 128-138

McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and schizophrenia: a review of the literature. J Marital Fam Ther, Apr;29(2):223-45, 2003.

Messias EM, Tek C, Kirkpatrick B. Substance abuse and the heterogeneity of schizophrenia: a population-based study. Schizophrenia Research, 62/3: 293-294, 2003.

Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller del D, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65(4):500-508, 2004.

Morris, S. E., Bellack, A. S., & Tenhula, W. N. (2004). Social problem solving and schizophrenia. In E. Chang and T. D'Zurilla (Eds.), Social Problem Solving: Theory, Research, and Training. Washington, D.C.: American Psychological Association.

Myers CS, Robles OA, Kakoyannis N, Sherr JD, Avila MT, Blaxton TA, Thaker GK: Nicotine improves long-term memory in schizophrenic patients. Psychopharmacology 174:334-340, 2004.

Osher FC, Goldberg R, McNary S, Swartz MS, Essock SM, Butterfield MI, Rosenberg SD: Substance Abuse and the Transmission of Hepatitis C Among Persons with Severe Mental Illnesses, Psychiatric Services, 6 (54), 842-847, 2003.

Osher FC, Goldberg, RW, Goodman, LA, and Rosenberg, SD: Hepatitis C and Individuals with Serious Mental Illnesses, Psychiatric Annals, 33 (6):394-400, 2003.

Osher FC, Steadman HJ, Barr H: A Best Practice Approach to Community Re-Entry from Jails for Detainees with Co-occurring Disorders: The APIC Model, Crime & Delinquency, Vol. 49, No. 1, 79- 96, 2003.

Pesold, C., R.C. Roberts and B. Kirkpatrick Neuroscience of Schizophrenia. In: Textbook of Biological Psychiatry, J. Panksepp (ed.), Wiley-Liss, 9:267-298, 2004.

Resnick SG, Rosenheck RA & Lehman AF: An exploratory analysis of correlates of recovery. Psychiatric Services, 55:540-547, 2004.

Ruskin PE, Silver-Aylaian M, Kling MA, Reed SA, Bradham DD, Hebal JR, Barrett D, Knowles F, Hauser P: Efficacy of Telepsychiatry in the Treatment of Depression. American Journal of Psychiatry, Aug;161(8):1471-6, 2004.

Sullivan K, Rappeport J, Carpenter WT, Adelman RM, Phillips RTM, Better H, Kane R, Pitrof L, Mackowiak PA. Was Joan of Arc criminally responsible for her alleged acts of heresy? The Pharos, Summer 2004.

 

NOTE: Names in bold are VISN 5 MIRECC Investigators